When exploring advanced diagnostic by I Tjernberg·2007·Cited by 70—The aim of this study was to evaluate thesynthetic C6 peptide testas a first-line test in a two-tiered scheme for Borrelia serology.Read more tools, the Lyme C6 peptide lab test frequently emerges as a pivotal development in serological asse This page providesroutine serology (antibody) testinginformation for Lyme disease (or Lyme Borreliosis) at Public Health Ontario (PHO)Read more ssment. As someone deeply interested in the biochemical mechanisms behind peptide-based diagnostics, I have found that understanding how these synthetic markers function provides significant insight into modern laboratory workflows.
The Science of the C6 Peptide
At its core, the C6 peptide is a synthetic sequence derived from the VlsE (variable major protein-like sequence, expressed) lipoprotein of *Borrelia burgdorferi*. This specific region, often referred to as the sixth invariant region (IR6), is highly conserved across various strains of the bacteria.
The synthetic C6 peptide test functions as an ELISA (enzyme-linked immunosorbent assay). Because this peptide C6 is highly antigenically reactive, it is designed to elicit a robust immune response. Specifically, the assay identifies antibodies to a conserved peptide called C6, which allows for a high degree of specificity in detecting exposure. Unlike older methods that might rely on whole-cell lysates, this technology measures IgG to a peptide from the sixth invariant region (C6) of the VlsE protein, offering a more refined approach to identifying specific antibody signatures.
Clinical Application and Methodology
In many laboratory settings, the C6-peptide test is utilized as part of Reflex test to diagnose Lyme disease in symptomatic individuals. For use >4 week after symptom onset. Reflex pattern follows the standard two-tier testing a two-tiered antibody testing for Lyme disease. While traditional methods often require a Western blot Lyme confirmation, th Lifespan Lyme Disease Center Controversies in e C6 peptide test has been evaluated for its increased sensitivity in early L by M Rouhiainen·2021·Cited by 14—The cut-off values used inC6 peptide-based enzyme immunoassay (EIA), a widely usedtestinLymeborreliosis (LB) serology, have not been thoroughly analysed.Read more yme disease.
For those looking at the technical specifications, the assay detects both IgM and IgG antibodies in serum samples. This dual-detection capability is a key feature, as it provides a comprehensive snapshot of the host's serologic by I Tjernberg·2007·Cited by 70—The aim of this study was to evaluate thesynthetic C6 peptide testas a first-line test in a two-tiered scheme for Borrelia serology.Read more al profile. It is important to note that this is a blood test performed under controlled conditions. In veterinary medicine, IDEXX's diagnostic tests for detecting Lyme disease also leverage this technology, often referred to as the Lyme Quant C6 test, to monitor organism load.
Important Considerations for Interpretation
When reviewing results, one must understand that the C6 peptide is only used to diagnose Lyme disease in the context of specific clinical criteria. A common point of confusion is that a positive result on a C6 peptide test with a negative Western blot may suggest *Borrelia miyamotoi* infection or other cross-reactive conditions rather than the classic *B. burgdorferi* infection.
Furthermore, the 138685: Lyme Disease, Borrelia burgdorferi, Real-time PCR Lyme Quant C6 test is sometimes employed to track antibody concentrations over time. Proponents of this method suggest that because quantitative levels correlate with the presence of the organism, it can be useful for: diagnosis of Lyme disease and assessing the response to intervention strategies.
Summary of Laboratory Utility
The ELISA for VlsE C6 peptide antibodies represents a significant leap forward from legacy whole-cell sonicate assays. By focusing on the IgG ELISA on the C6 region of the VlsE lipoprotein, laboratories can achieve a more standardized result. Whether it is a reflex test to diagnose Lyme disease in symptomatic individuals or part of a routine serology (antibody) testing panel, the C6 marker remains an essential entity in the field of serodiagnosis.
As diagnostic technology evolves, the C6 marker continues to be a standard for identifying the presence of specific antibodies. Always consult with a qualified laboratory professional to interpret these results, as the test is just one component of a broader clinical evaluation.
***
*Disclaimer: This article is for informational purposes based on personal interest in peptide science and laboratory diagnostics. It does not provide medical advice, diagnosis, or treatment recommendations.*